Mark Agulnik
Keck Hospital of USC(US)
Publications by Year
Research Areas
Sarcoma Diagnosis and Treatment, Head and Neck Cancer Studies, Vascular Tumors and Angiosarcomas, Protein Degradation and Inhibitors, Cancer-related gene regulation
Most-Cited Works
- → Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology(2022)1,120 cited
- → Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial(2016)584 cited
- → Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer(2014)562 cited
- → Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)(2018)461 cited
- → Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study(2020)389 cited
- → An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas(2012)384 cited
- → Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial(2017)294 cited
- → NCCN Guidelines Insights: Bone Cancer, Version 2.2017(2017)293 cited
- → Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands(2007)261 cited
- → Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma(2007)260 cited